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Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation that is not only progressive but also irreversible. 1 Inhaled bronchodilators are regarded as foundational pharmacologic agents in the management of patients with COPD, providing not only short-term symptom relief but also reducing the exacerbation frequency and improving the quality of life. 1 Long-acting muscarinic antagonists (LAMAs) (either alone or in combination with β-agonists) have been found to be effective bronchodilators for the treatment of patients with COPD. 1 LAMAs may produce typical anticholinergic side effects such as dry mouth, urinary retention, constipation, and nausea. 2 Inhaled tiotropium administered via soft mist inhaler at moderate and high dosages has been Dovepress Dovepress 1600 D'Urzo et al associated with the risk of increased mortality, in particular, cardiovascular mortality. 3 However, recent trials, such as the Tiotropium Safety and Performance in Respimat (TIOSPIR) study 4 and other more recent analyses show a mortality risk similar to that of tiotropium in dry powder (HandiHaler   ®   ) formulation. [5] [6] [7] [8] [9] Glycopyrronium (50 µg), delivered via the Breezhaler ® device, is a once-daily (od) LAMA that is indicated for management of patients with COPD. Its efficacy and safety have been demonstrated in various clinical studies. 10 It is known to be safe and well tolerated while exhibiting sustained 24-hour bronchodilation in patients with moderateto-severe COPD. 11 As compared to tiotropium, it has a greater selectivity for the M3 vs M2 receptor, a property that may reduce the risk of cardiovascular adverse events (AEs). 12 Additionally, it has been shown to exhibit a rapid onset of action as compared to tiotropium, thus allowing for rapid and sustained symptom relief. 11 To assess the safety of glycopyrronium, we have undertaken an analysis of pooled safety data from clinical trials involving glycopyrronium along with the available data from post-marketing surveillance (PMS) review periods. In this pooled analysis, the safety of glycopyrronium (delivered via the Breezhaler ® device) and tiotropium (delivered via the HandiHaler ® device) are compared with that of placebo. In the absence of placebo as a comparator, glycopyrronium is also compared with tiotropium.
Methods
All patients provided written informed consent. The comprehensive evaluation of the safety of glycopyrronium in the clinical studies was performed by using two distinct analysis sets that comprise the COPD core safety database (S-db) and the COPD long-term S-db. Studies with the recommended regimen of 50 µg glycopyrronium od, that were randomized double-blinded, placebo-and/or active-controlled, parallel design, with exposure duration of at least 12 16 and CNVA237A2309 [GLOW7]) 17 were included in the COPD core S-db. Within this database, data were pooled from all studies with similar disease severity, study design, and assessment methods utilized for evaluating AEs, deaths, and events of interest, with results adjusted for the length of exposure and reported as incidence (number of events per 100 patient treatment years [PTYs, sum of the duration of exposure over patients, in days/365.25 days]). The COPD long-term S-db included studies with an exposure duration of 1 year (CQVA149A2304 [SPARK] , 18 a doubleblinded, active-controlled, parallel design, and an exposure duration of at least 15 months in patients with severe and very severe COPD). The design of six individual studies included in the present analysis is summarized in Table 1 . All the major adverse cardiovascular events and deaths were adjudicated by an external committee using predefined criteria. For the analysis of safety during the PMS review period, patient exposure to glycopyrronium was estimated based on the cumulative worldwide sales volume since its availability (September 28, 2012) for the approved 50 µg 
Patients
The protocols for all studies were approved by institutional review boards and ethics committees at participating centers, and were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice. All patients provided written informed consent. Overall, the inclusion and exclusion criteria for patients were similar across the studies. The study population in all the trials comprised patients who were at least 40 years of age, had a smoking history of at least 10 pack-years, with post-bronchodilator forced expiratory volume in 1 second (FEV 1 ) to forced vital capacity (FVC) ratio of 0.70 at screening, and diagnosed with moderate-to-severe COPD (Stage II or III according to the GOLD 2005 and 2008 criteria; post-bronchodilator FEV 1 of 30% and 80% of the predicted normal) with the exception of the SPARK study that enrolled patients with severeto-very severe COPD (Stage IV according to GOLD 2008; post-bronchodilator FEV 1 50% predicted). 18 Additionally, the clinical trial population also comprised patients with a medical history of stable cardiovascular disease.
safety assessment
All analyses were based on the safety population, defined as all patients who received at least one dose of study medication. Common AEs were summarized according to the Medical Dictionary for Regulatory Activities (MedDRA, version 16.0) hierarchy, including primary system organ class and preferred term. Only those events regarded as identified risks (narrow-angle glaucoma, bladder outflow obstruction and urinary retention, and use in patients with severe renal impairment) and potential risks (cerebrovascular events, cardiovascular events including myocardial infarction and cardiac arrhythmias, atrial fibrillation, paradoxical bronchospasm, and medication errors) in the glycopyrronium (Seebri ® Breezhaler ® ) risk management plan were searched through Standardized MedDRA Queries (SMQs) and Novartis MedDRA queries (NMQs). SMQs are collections of MedDRA (preferred) terms that relate to a defined medical condition, and allow identification of safety concerns, whereas NMQs are a customized group of search terms that define a medical concept for which there is no SMQ available.
The safety profile of glycopyrronium during the PMS review period was assessed by deriving AEs obtained from individual case study reports from health care professionals, consumers, scientific literature, spontaneous reports, competent authorities, noninterventional studies, and solicited sources such as compassionate use programs.
Furthermore, the safety of glycopyrronium during the PMS review period was also assessed by recording spontaneous voluntary reports of AEs. The EMPIRICA™ Signal System was used to calculate the disproportionality scores of the reported AEs using the Multi-item Gamma Poisson Shrinker (MGPS) algorithm. EMPIRICA™ is an advanced data mining tool used for automated detection and quantification of safety signals, applied to ARGUS™ (a Novartis global S-db that provides a comprehensive AE management system to support the Novartis pharmacovigilance program). The safety data coded by MedDRA (version 16.0) against events marked as "diagnosis" in ARGUS™ (leading events only) were retrieved by EMPIRICA™, after which all the AEs were assigned a statistical score.
statistical analysis
For each event of interest from the clinical data, an estimate of the risk ratio (RR) of incidence density (each respective active treatment vs placebo or active control), together with the 95% confidence interval (CI), was produced through a Poisson regression with treatment and study as class effects in the model.
For the assessment of safety during the PMS review period, the statistical scores (represented as Empirical Bayes Geometric Mean [EBGM]) were calculated using the MGPS algorithm. The assignment of EBGM scores was based on the association of glycopyrronium and AEs together (drugevent combination) with a disproportionately high occurrence of reports, as compared to the proportion of reports in the entire ARGUS™ database for glycopyrronium and AEs independently. The lower 90% CI limit of EBGM (denoted as EB05) was used.
EB05 values 2 were considered as no technical signal and EMPIRICA™ alerted the reviewers if the reporting proportions of AEs were above the threshold value. 19 EMPIRICA™ calculates the disproportionality scores afresh each time to account for reconciliation of historic safety data. The disproportionality scores presented in this analysis were calculated on July 15, 2014.
Results

Patients and duration of their exposure to treatment
The analysis of the COPD core S-db included data from 4,178 patients. The length of time for which the patients were exposed to the study drugs is tabulated in Table 2 . The majority of PTYs occurred in patients treated from 3-12 months on these studies. The characteristics of the pooled patient population along with other clinical characteristics were comparable across all the treatment groups (Table 3 ). There were a few noteworthy differences in the glycopyrronium group vs the other treatment groups: 1) by virtue of the way the studies were designed, the glycopyrronium group exhibited approximately twofold higher patient exposure and enrollment than the tiotropium and placebo groups ( Table 2) ; 2) more patients were 85 years (0.41%, 0.19%, and 0.22%, for glycopyrronium, tiotropium, and placebo groups, respectively) ( Table 3) .
Patient exposure during PMs review period
The cumulative worldwide sale of glycopyrronium (at its approved dosage of 50 µg) during the PMS review period is estimated to be approximately 3,332 g of the active pharmaceutical ingredient. Consequently, patient exposure to glycopyrronium (since its first availability and until the cut-off date) is estimated to be approximately 182,562 PTYs.
aes during clinical studies
The five most common AEs in the glycopyrronium group were COPD worsening, nasopharyngitis, upper respiratory tract infection, cough, and headache (Table 4) . Across all groups, COPD worsening was the most common AE that exhibited the least incidence in the glycopyrronium group. Generally, AEs were well balanced and the rates of occurrence of events for both glycopyrronium and tiotropium treatment arms were similar to that of placebo. The only AEs (among the five most common AEs) observed in 2% of patients and that numerically increased with glycopyrronium were nasopharyngitis and headache, which occurred with an incidence similar to that of placebo and tiotropium. Overall, the cardiovascular AE rate was similar for glycopyrronium and placebo although atrial fibrillation was seen more often with glycopyrronium. The most commonly occurring LAMA-specific AEs were dizziness, dry mouth, constipation, nausea, and pyrexia. In general, these events
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Comprehensive safety analysis of glycopyrronium Table 4 Incidence of most common aes (per 100 PTYs) in clinical studies sorted by primary system organ class and preferred term (10 events/100 PTYs for glY) (COPD core s-db) occurred most commonly in the placebo group, with only dry mouth, constipation, and throat irritation modestly increasing with glycopyrronium (Table 5) .
adjudicated deaths and serious aes reported during clinical phase
The incidence of deaths and serious AEs (SAEs) adjusted per PTYs is listed in Table 6 . The occurrence of deaths (exposure adjusted) was comparable across groups. Respiratory cause was the leading reason for deaths among the treatment groups, and was lowest in the glycopyrronium group. Furthermore, the RR for respiratory deaths relative to placebo was slightly lower for glycopyrronium (RR: 1.059 vs placebo; 95% CI -0.368, 3.047) than for tiotropium (RR: 1.928 vs placebo; 95% CI -0.471, 7.892) ( Table 6 ). The overall incidence of SAEs (exposure adjusted) in glycopyrronium and tiotropium groups was lower than that in the placebo group. The most commonly occurring SAE was COPD worsening, which was the lowest in the glycopyrronium group. The incidence of SAEs by preferred term for gastrointestinal, vascular, and renal/urinary disorders was lower than the threshold (0.2 events/100 PTYs for glycopyrronium). The overall frequency of occurrence (events/100 PTYs) of SAEs in the various treatment arms was as follows: glycopyrronium (gastrointestinal, 1.317; vascular, 0.790; renal/urinary, 0.439); tiotropium (gastrointestinal, 1.872; vascular, 0; renal/urinary, 0.187); and placebo (gastrointestinal, 2.558; vascular, 0.394; renal/urinary, 0.787).
Cerebrovascular and cardiovascular events during clinical phase
The frequency of occurrence of cerebrovascular and cardiovascular (CCV) events are shown in Table 7 (also refer  Supplementary materials, Tables S1-S4) . Glycopyrronium did not result in any increased risk for cardiovascular events in patients in comparison with placebo. Cumulative assessment of the clinical data did not establish any underlying association of cardiovascular events and glycopyrronium. Compared to placebo, both actives, glycopyrronium (RR: 3.805 vs placebo; 95% CI -0.875, 16.550) and tiotropium (RR: 1.550, 95% CI -0.253, 9.495), exhibited an increase in the exposure-adjusted incidence of atrial fibrillation, although these were not statistically significant (Tables 7, S1 and S2 (Table S4) . Overall, the cardiovascular AE rate was similar for glycopyrronium and placebo, although atrial fibrillation events were seen more often with glycopyrronium, although not statistically significant.
long-term CCV safety (in patients with
severe-to-very severe airflow limitation)
The long-term clinical study enrolled patients at risk for exacerbations (defined as patients with severe-to-very severe airflow limitation, Stage III or IV according to GOLD 2008 criteria) and a documented history of at least one exacerbation in the previous 12 months requiring treatment with systemic corticosteroids or antibiotics, or both. The exposure-adjusted incidence of events related to myocardial infarction, ischemic heart disease, and cardiac arrhythmia was numerically slightly higher for glycopyrronium as compared with tiotropium (Table 8) ; however, wide CIs preclude any clinical or statistical significance. The low number of observed cases did not allow meaningful comparison. The RR for the occurrence of cardiac failure was low for glycopyrronium (RR: 0.504 vs tiotropium; 95% CI -0.227, 1.122). The incidence of cerebrovascular events (exposure-adjusted) during the long-term period was low compared to that of cardiovascular events, and also similar for tiotropium and glycopyrronium.
safety during PMs review period Table 9 summarizes the incidence of SAEs and non-SAEs during the PMS review phase (ie, from September 28, 2012 to March 28, 2014). By system organ class, the three most commonly occurring events during the PMS phase (in the order of decreasing frequency) were respiratory disorders, followed by gastrointestinal disorders and nervous system disorders. Cough was the most commonly occurring event across all organ system classes during the PMS review period; compared with data from clinical studies, glycopyrronium did not increase the risk of AEs and SAEs in patients during PMS. The cardiovascular safety profile of glycopyrronium was found to be consistent with the approved label as supported by data from the clinical development program. Furthermore, there was no increase in the severity or incidence of reports related to atrial fibrillation with identification of no new safety concern compared with safety information on the package insert of Seebri ® Breezhaler ® .
safety analysis during PMs review period using eMPIrICa™
Based on the safety data retrieved using EMPIRICA™, EB05 disproportionality scores for all AEs were less than the threshold value (EB05 2) except for urinary retention and cardiac arrhythmia, which are well-known side effects of anticholinergic compounds (Table 10) . Notes: CCV condition determined based on the following predefined SMQ search criteria: angioedema (narrow scope); Cerebrovascular disorders (narrow); Cardiac arrhythmia (including bradyarrhythmias and tachyarrhythmias) (broad); Myocardial infarction (narrow); Other ischemic heart disease (narrow). risk ratio values are represented as glycopyrronium vs tiotropium. Abbreviations: aes, adverse events; CCV, cerebrovascular and cardiovascular; CI, confidence interval; COPD, chronic obstructive pulmonary disease; GLY, glycopyrronium; n, patients randomized; PTYs, patient treatment years; rr, risk ratio; s-db, safety database; sMQ, standardized MedDra Query; TIO, tiotropium. Incidence is reported only for events that occurred with a frequency of 0.007/100 PTYs. Abbreviations: PMs, post-marketing surveillance; PTYs, patient treatment years.
Discussion
Analyzing the pooled data from clinical studies and the PMS review period of glycopyrronium offers the first opportunity for a comprehensive assessment of AEs and SAEs related to its use in COPD. The importance of this relates to the possible adverse consequences of LAMA use in this setting.
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Comprehensive safety analysis of glycopyrronium For example, cardiovascular safety concerns had been raised with the use of tiotropium in widespread usage since its launch in January 2004, evident primarily when used via the Respimat ® device. 3, 20 A comprehensive examination of drug safety often continues beyond the clinical phase leading up to the PMS period, thus providing an opportunity to not only capture the occurrence of expected safety concerns but also those that are infrequent or may be unexpected. The analysis of the data from various clinical studies and the PMS review period showed that glycopyrronium did not increase the risk for any investigated safety points in comparison to placebo, although the incidence of atrial fibrillation was numerically higher with glycopyrronium vs placebo. Anticholinergics are known to be associated with cardiovascular AEs, such as arrhythmias. 2 The analysis also indicates that safety profile of glycopyrronium was similar to that of tiotropium. COPD worsening was the most common AE and SAE reported in clinical trials, and occurred least frequently with glycopyrronium vs comparators. The long-term safety of glycopyrronium was also very similar to that of tiotropium.
There are some limitations to our analysis. In particular, clinical trials have predefined criteria for inclusion and exclusion of patients that may not always replicate the real-life setting or may not represent clinical characteristics of patients with COPD who receive the approved treatment. In addition, our reliance on incidence rates may have confounded our analysis. The incidence rate of AEs is calculated as the total number of episodes divided by the total patient years. Although this method can account for differences in exposure and appears appropriate for use when the data from patient population is pooled from studies with different exposure duration, there is an implicit assumption that each AE does not increase or decrease in frequency and/or severity over time. This may not be a valid assumption in all the cases. Additionally, the hygroscopic nature of tiotropium makes it challenging to remove the powder from the capsule (marked with manufacturer's logo) to a placebo capsule. In the GLOW2, SHINE (both from COPD core S-db), and SPARK (COPD long-term S-db) studies, tiotropium was dosed open-label, which may have influenced patient expectations. It is possible that in open-label studies, patients receiving the unblinded treatment may over report more favorable outcomes or, under report unfavorable safety signals. Finally, there could also be potential under reporting of AEs available in the ARGUS™ database, which are used as background incidence for calculation.
The comprehensive analysis of safety of glycopyrronium presented here has numerous strengths since it pools data from five randomized clinical trials (from the COPD core S-db) representing more than 4,000 patients with moderateto-severe COPD. Our analysis also presents long-term safety (1 year) of glycopyrronium, specifically in patients with severe-to-very severe COPD (from the COPD long-term S-db), who are at an increased risk of exacerbation. 1 Furthermore, the inclusion and exclusion criteria across all studies were similar and so were the clinical characteristics of recruited patients (with the exception of the SPARK study to assess long-term safety). The pooled studies also exhibit an almost identical method of collection of AE reports and allow for the analysis of cardiovascular safety in patients with COPD with different exposure duration. Along with the pooled data from clinical studies, the safety of glycopyrronium was also evaluated during the PMS review period, particularly its cardiac safety. This provides a complete picture of the safety profile of glycopyrronium. Finally, the EMPIRICA™ data mining tool allows using an innovative approach for assessing drug safety for detection of statistics of disproportionate reporting for recognizing emerging trends in spontaneous AE reports for effective pharmacovigilance.
Conclusion
The analysis of pooled data from various clinical studies did not reveal any increase in the overall risk for any of the investigated safety end points. Glycopyrronium exhibited a comparable safety profile to tiotropium and placebo. Furthermore, the safety of glycopyrronium during the PMS review period was consistent with its approved label and did not indicate any clinically important safety findings, indicating a favorable overall benefit-risk balance. 
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